BioNTech’s MarNT facility receives EMA approval, boosting COVID-19 vaccine productivity capacity by billion billion doses

by

BioNTech SE BNTX,
+ 1.72%
the European Medicines Agency (EMA) said on Friday it has approved its Marburg facility in Germany for the manufacture of the COVID-19 vaccine drug product, which would increase annual vaccine production capacity by one billion each year when fully operational. BioNTech, which is with US-based partner Pfizer Inc. PFE,
+ 0.22%
making the COVID-19 vaccine, he said, he can now deliver drug production bonds of the vaccine to partner sites, for sterile filling and finishing, and the first bags of the vaccines are expected to be delivered. made at the Marburg site delivered in the second half of April. The company said 50,000 steps are needed from manufacturing the drug, mRNA, to most drugs that can be filled and finished. BioNTech stock rose 1.6% in morning trading, while Pfizer shares gained 0.3% and the S&P 500 SPX,
+ 0.65%
support at 0.5%.

.Source